
Sign up to save your podcasts
Or


In the first segment, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis. In the second part of the podcast, Dr. Jeff Burns talks to neurologist Dr. Daniel Gibbs about his Alzheimer's disease diagnosis and experience participating in a clinical trial for aducanumab.
By American Academy of Neurology4.7
283283 ratings
In the first segment, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis. In the second part of the podcast, Dr. Jeff Burns talks to neurologist Dr. Daniel Gibbs about his Alzheimer's disease diagnosis and experience participating in a clinical trial for aducanumab.

320 Listeners

497 Listeners

51 Listeners

287 Listeners

3,341 Listeners

13 Listeners

1,153 Listeners

21 Listeners

194 Listeners

361 Listeners

513 Listeners

133 Listeners

180 Listeners

370 Listeners

79 Listeners